---
figid: PMC8175106__10-1055-s-0041-1729743-i001282-1
figtitle: Management of Venous Malformations
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8175106
filename: 10-1055-s-0041-1729743-i001282-1.jpg
figlink: /pmc/articles/PMC8175106/figure/FI001282-1/
number: F1
caption: Signal pathway involved in the pathogenesis of venous malformations and targets
  of systemic therapy. PI3K-AKT-mTOR signaling pathway and relevant vascular anomalies
  associated with each enzyme variant. Sirolimus inhibits mTOR. Alpelisib inhibits
  PI3K. AKT, Ak strain transforming oncogene, or protein kinase B; CLOVES, congenital
  lipomatous overgrowth, vascular malformations, epidermal PIE 2/RTK, angiopoetin
  receptor and y60sine kinase, nevi, and spine/skeletal anomalies; ERK, extracellular
  receptor kinase; MEK, mitogen-activated protein kinase; mTOR, mammalian target of
  rapamycin; PI3K, phosphatidylinositol 3-kinase; PIK3CA, phosphatidylinositol 4,5-bisphosphate
  3-kinase catalytic subunit α; RAF, rapidly accelerated fibrosarcoma kinase; RAS,
  rat sarcoma oncogene.
papertitle: Management of Venous Malformations.
reftext: Michael Acord, et al. Semin Intervent Radiol. 2021 Jun;38(2):215-225.
year: '2021'
doi: 10.1055/s-0041-1729743
journal_title: Seminars in Interventional Radiology
journal_nlm_ta: Semin Intervent Radiol
publisher_name: Thieme Medical Publishers, Inc.
keywords: venous malformation | sclerotherapy | pediatric | interventional radiology
  | embolization
automl_pathway: 0.939456
figid_alias: PMC8175106__F1
figtype: Figure
redirect_from: /figures/PMC8175106__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8175106__10-1055-s-0041-1729743-i001282-1.html
  '@type': Dataset
  description: Signal pathway involved in the pathogenesis of venous malformations
    and targets of systemic therapy. PI3K-AKT-mTOR signaling pathway and relevant
    vascular anomalies associated with each enzyme variant. Sirolimus inhibits mTOR.
    Alpelisib inhibits PI3K. AKT, Ak strain transforming oncogene, or protein kinase
    B; CLOVES, congenital lipomatous overgrowth, vascular malformations, epidermal
    PIE 2/RTK, angiopoetin receptor and y60sine kinase, nevi, and spine/skeletal anomalies;
    ERK, extracellular receptor kinase; MEK, mitogen-activated protein kinase; mTOR,
    mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase; PIK3CA, phosphatidylinositol
    4,5-bisphosphate 3-kinase catalytic subunit α; RAF, rapidly accelerated fibrosarcoma
    kinase; RAS, rat sarcoma oncogene.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Erk7
  - rl
  - ras
  - Ras64B
  - Ras85D
  - MKP-4
  - p38b
  - Raf
  - Dsor1
  - Mtk
  - Tie
  - InR
  - Akt
  - Mtor
  - Tor
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - syndrome
  - EPHB2
  - MAPK1
  - MAPK3
  - KRAS
  - HRAS
  - NRAS
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
---
